Generate Biomedicines is a new kind of therapeutics company – existing at the intersection of machine learning, biological engineering, and medicine – pioneering Generative Biology to create breakthrough medicines where novel therapeutics are computationally generated, instead of being discovered. Generate has built a machine learning-powered biomedicines platform with the potential to generate new drugs across a wide range of biologic modalities. This platform represents a potentially fundamental shift in what is possible in the field of biotherapeutic development. We pursue this audacious vision because we believe in the unique and revolutionary power of generative biology to radically transform the lives of billions, with an outsized opportunity for patients in need. We are seeking collaborative, relentless problem solvers that share our passion for impact to join us!

OpenAI's DALL.E 2 has been making it big with text-to-image models that easily generate pictures from textual descriptions. Earlier this week, two biotech labs--Generate Biomedicines and David Baker's Group--relied on generative AI, particularly diffusion models, to come up with new protein structures and, eventually, better drugs. Boston-based therapeutics company Generate Biomedicines announced a programme called Chroma which, according to the company, is the "DALL-E 2 of biology". Similarly, biologist David Baker's team from the University of Washington has also come up with RoseTTAFoldDiffusion. The model can build accurate designs for new proteins that can be brought to life in the lab.

Today, two labs separately announced programs that use diffusion models to generate designs for novel proteins with more precision than ever before. Generate Biomedicines, a Boston-based startup, revealed a program called Chroma, which the company describes as the "DALL-E 2 of biology." At the same time, a team at the University of Washington led by biologist David Baker has built a similar program called RoseTTAFold Diffusion. In a preprint paper posted online today, Baker and his colleagues show that their model can generate precise designs for novel proteins that can then be brought to life in the lab. "We're generating proteins with really no similarity to existing ones," says Brian Trippe, one of the co-developers of RoseTTAFold. These protein generators can be directed to produce designs for proteins with specific properties, such as shape or size or function.

Generate Biomedicines is a new kind of therapeutics company – existing at the intersection of machine learning, biological engineering, and medicine – pioneering Generative Biology to create breakthrough medicines where novel therapeutics are computationally generated, instead of being discovered. Generate has built a machine learning-powered biomedicines platform with the potential to generate new drugs across a wide range of biologic modalities. This platform represents a potentially fundamental shift in what is possible in the field of biotherapeutic development. We pursue this audacious vision because we believe in the unique and revolutionary power of generative biology to radically transform the lives of billions, with an outsized opportunity for patients in need. We are seeking collaborative, relentless problem solvers that share our passion for impact to join us!